GNTANasdaqBiological Products, (No Diagnostic Substances)

Genenta Science S.p.A.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$0.66−0.02 (-2.40%)

Close on Oct 19, 2026

Genenta Science S.p.A. income statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Research & Development	2.70	4.81	6.47	5.34	3.39	4.69	3.70
General & Administrative	3.90	4.95	5.26	5.71	2.30	0.90	0.92
Operating Expenses	6.60	9.76	12	11	5.69	5.59	4.62
Operating Income	-6.60	-9.76	-12	-11	-5.69	-5.59	-4.62
Other Non-Operating Income	0.07	0.85	0.09	2.57	0.16	0.00	0.03
Pretax Income	-6.53	-8.91	-12	-8.48	-5.53	-5.59	-4.60
Net Income	-6.53	-8.91	-12	-8.48	-5.53	-5.59	-4.60
EPS (Basic)(per share)	–	–	-0.64	-0.47	-0.37	–	–
EPS (Diluted)(per share)	-0.33	-0.49	-0.64	-0.47	-0.37	–	–
Shares Outstanding (Basic, Weighted)(shares)	20	18	18	18	15	–	–
Shares Outstanding (Diluted, Weighted)(shares)	20	18	18	18	15	–	–
EBITDA	-6.58	-9.72	-12	-11	-5.68	-5.59	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -38.0%

Financial strength

Current ratio: 14.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 261.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.